Document Type

Journal Article


Scientific Research Publishing


School of Medical Sciences / Centre of Excellence for Alzheimer's Disease Research and Care




Edith Cowan University

McCusker Alzheimer’s Research Foundation

National Health and Medical Research Council


Martins, I. J. (2016). Magnesium therapy prevents senescence with the reversal of diabetes and Alzheimer’s disease. Health, 8(7), 694-710.


In the current global epidemic for Non Alcoholic Fatty Liver Disease (NAFLD), diabetes and neurodegenerative diseases such as Alzheimer’s disease there has been a major interest in magnesium therapy to delay the severity of NAFLD, Type 3 diabetes and neurodegeneration in the developing and developed world. The objective of magnesium therapy is to activate the anti-aging gene Sirtuin 1 (Sirt1) to prevent cardiovascular disease, NAFLD and diabetes. Reduced consumption of nutrients such as fatty acids, glucose, cholesterol and increased magnesium consumption is closely linked to reduced bacterial lipopolysaccharides (LPS) and activation of Sirt1 relevant to active nuclear and mitochondria interactions with the prevention of myocardial infarction and Type 3 diabetes. Magnesium deficiency and its effects on Sirt1 regulation have become important with magnesium deficiency associated with appetite dysregulation, senescence, glucose/nitric oxide dyshomeostasis, increased ceramide and toxic amyloid beta formation. Magnesium therapy activates the peripheral sink amyloid beta clearance pathway with the reversal of cell senescence associated with various chronic diseases such as cardiovascular disease, Type 3 diabetes and Alzheimer’s disease.



Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Included in

Diseases Commons